Mirae Asset Global Etfs Holdings Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 38,390 shares of CRNX stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,390Holding current value
$2.33 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
247Shares Held
78.5MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$378 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$371 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$280 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$274 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$267 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.26B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...